Alnylam Pharmaceuticals (ALNY) Stock: Buy, Sell, or Hold?
ALNY - Alnylam Pharmaceuticals, Inc.
$224.03
-3.25 (-1.43%)
âŧ
5d:
-3.36%
30d:
-10.24%
90d:
-19.53%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 29, 2026
4d
Get Alerted When ALNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ALNY is fairly priced but lacks strong directional signals. At -8.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ALNY is fairly priced but lacks strong directional signals. At -8.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$575.11
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$357.10
37.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALNY is currently trading at $224.03, which is considered slightly low relative to its 30-day fair value range of $224.91 to $247.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.1) compared to its historical average (23.9). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ALNY is in a strong downtrend. The price is currently testing key support at $221.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALNY scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $368.70 (+64.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALNY is in a strong downtrend. The price is currently testing key support at $221.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALNY scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $368.70 (+64.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$224.91 -
$247.56
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding ALNY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.6% below Wall St target ($368.70)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$224.91 -
$247.56
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$221.56
Resistance Level
$238.96
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.13
Wall Street Target
$368.70
(+64.6%)
Revenue Growth (YoY)
66.9%
Profit Margin
16.1%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
18.1 vs 23.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$204.32
(-9%)
2-Year Target
$186.34
(-17%)
3-Year Target
$169.94
(-24%)
3-Yr Target (if PE normalizes)
(PE: 18â24)
$224.02
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 39.4%)
$664.95
(+197%)
Base:
(SPY PE: 18.1, Growth: 39.4%)
$607.02
(+171%)
Bear:
(PE: 15.4, Growth: 39.4%)
$515.97
(+130%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 38.33 | Current EPS (TTM): $5.93
Bull Case
$500.02
(+123%)
Analyst growth 100.0%, PE expands to 42.2
Base Case
$454.56
(+103%)
Market implied 100.0%, PE stable at 38.3
Bear Case
$154.55
(-31%)
Severe decline -20.0%, PE contracts to 32.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 23.9
Stabilization Target:
$295.33
(+31.8%)
PE Expansion Potential:
+31.8%
Share & Embed Analysis
Last updated: October 24, 2026 12:19 PM ET
Data refreshes hourly during market hours. Next update: 1:19 PM
Data refreshes hourly during market hours. Next update: 1:19 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
Advanced ALNY Option Strategies
Professional options setups generated by AI based on today's ALNY price and gamma walls.
